Apimeds Pharmaceuticals (APUS) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing Apitox, a bee venom-based biologic for osteoarthritis (OA) and multiple sclerosis (MS).

• Holds exclusive U.S. rights to Apitox via a sublicensable, royalty-bearing license from Apimeds Korea.

• No U.S. product revenue to date; Apitox is marketed in South Korea as Apitoxin but not FDA-approved in the U.S.

• Business strategy focuses on advancing Apitox through Phase III trials for knee OA and early MS studies, with plans for out-licensing and collaborations.

• Manufacturing is outsourced, with proprietary processes and trade secrets providing protection.

Financial performance and metrics

• No revenue generated as of September 30, 2024; company is pre-commercialization.

• Net loss of $1,078,357 for the nine months ended September 30, 2024, and $777,694 for the year ended December 31, 2023.

• Cash balance of $26,571 as of September 30, 2024; accumulated deficit of $4,080,291.

• Operating expenses driven by R&D and increased general and administrative costs related to IPO preparation.

• Auditor's report includes a going concern explanatory paragraph due to recurring losses and limited cash runway.

Use of proceeds and capital allocation

• Estimated net proceeds of $16.1 million (or $18.5 million if over-allotment is exercised) at $4.00 per share IPO price.

• Proceeds to fund Phase III knee OA trial (~$10M), initiate at least one MS study (~$1.5M), manufacturing (~$1M), repay short-term debt (~$0.7M), and for working capital and general corporate purposes.

• Proceeds expected to fund operations for at least 12 months post-offering.